Sherin Rouhani, MD PhD

Inpatient oncologist and immunologist at MGH. Opinions are my own.

[JCO Precision Oncology @JCOPO_ASCO]

👀 See what’s popular this week in #JCOPO:

STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage NSCLC ➡️ https://t.co/sjZtkRo09E #lcsm @seanpitroda @lfspurr @sgutiontov @ajuloorimd @michaelsbinkley @srouhani1 @BLoo_LT_SABR @RohanKatipally

[Rohan Katipally @RohanKatipally]

Proud to present our work, now online @JCOPO_ASCO: "STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small Cell Lung Cancer"

https://t.co/jRxRmplBgQ

So thankful for our numerous collaborators across multiple departments and institutions

Tweetorial 👇

[Lecia Sequist, MD, MPH, FASCO @LeciaSequist]

So proud of @kreynoldsMD and her amazing team @MGHCancerCenter for pioneering the IO complications inpt team 5 years ago. Has been the foundation on which multi-specialty expertise in IO tox has been built across our general hospital! #TrailBlazer #WIO 🙌https://t.co/zhGCW1UuMg

[Patrick Forde @FordePatrick]

Patient-centered summary of the #CheckMate816 neoadjuvant chemo-immunotherapy clinical trial. This is a new treatment for patients with stage 1-3 non-small-cell lung cancer that can be removed by surgery. The summary may be useful for clinicians & patients. #lcsm @LUNGevity

[Sherin Rouhani, MD PhD @srouhani1]

@inas_md So sorry for your loss, Inas 💔

[Sherin Rouhani, MD PhD @srouhani1]

More data emerging emphasizing the importance of boosters against Omicron - 2 doses of mRNA vax are good against original or delta strains, but for omicron the neutralization ability after 2 doses isn't great. Omicron neutralization improves substantially after booster!

[Balazs Lab @BalazsLab]

Here's what we saw for people who got Moderna:

6/16

[Balazs Lab @BalazsLab]

Here's what the data looked like for people who got Pfizer:

7/16

[Sherin Rouhani, MD PhD @srouhani1]

So excited to share the preprint of our study looking at mechanisms of progression to severe COVID! Couldn’t have done it without co-first authors @HowellJollyBody and @jontrujilloNM, @jovianyu & entire team. #TeamScience for the win!

[Tatiana Prowell, MD @tmprowell]

📣 #MedTwitter #FDA granted emerg use auth to AZ long-acting Ab cocktail (Evusheld) for #COVID19 PRE-exposure prophylaxis in mod-severe immunocompromised (age 12+ & 40+ kg). Two IM injections, may repeat q6 mos. At least 2w post vax. ⚠️ Not PEP/treatment
https://t.co/IUIH7dDToY

[Ivy Elkins @ivybelkins]

Join me, @marinagarassino & @srouhani1 for a webinar on the difference btwn basic science & clinical science with respect to COVID Vax and #LungCancer. Register at the link below! OPEN TO ALL - gift card raffle for all attendees! #lcsm @EGFRResisters @UCCancerCenter @UCMOCECHE

[Jarushka Naidoo @DrJNaidoo]

Interesting study ⁦@CCR_AACR⁩ shows high-dose steroids (>60mg pred) for early irAEs (within 8wks antiPD1) for melanoma is assoc with poorer:
- post-irAE PFS
- post-irAE OS

validated by multinational cohort& confirmed by sensitivity analysis ⁦ https://t.co/Klc68dPML8

[Sean Pitroda, M.D. @SeanPitroda]

CDKN2A LOF as a predictor of ICB resistance in NSCLC: https://t.co/3ziuxUMBrR.

[Nik Joshi @Joshilabyale]

Excited for the opportunity to participate in the @EarlyImmunology series next Tuesday at 12pm ET.

I’ll be talking on unpublished new models of peripheral T cell tolerance and how immune checkpoint blockade can lead to immunopathology.

[Sherin Rouhani, MD PhD @srouhani1]

Work from @ClydoMary and @WeeChua7 !

[Lurie Children's @LurieChildrens]

Governor @JBPritzker has proclaimed October 4,2021 as TEN-4 Day in IL to honor the importance of recognizing concerning bruises and injuries on young children and to emphasize the importance of training adults to recognize, report, and prevent child abuse. https://t.co/nu8TXs66C2

[ESMO - Eur. Oncology @myESMO]

Presented at #ESMO21, first concrete results regarding #COVID19vaccine in #cancer patients: robust data proves efficacy, safety and that a 3rd booster dose may improve immune response in this population. @APassaroMD #visualabstract 👉 https://t.co/Benr04j9Ho
#COVID19nCancer

[Sherin Rouhani, MD PhD @srouhani1]

Important work from @DoreenEzeife & team. Doing more testing up-front with liquid biopsy + tissue NGS actually SAVES the health system money, and more importantly gets patients the best first-line treatment. Time to update our standard workflow... @marinagarassino

[Stephen V Liu, MD @StephenVLiu]

#WCLC21 Congratulations to Dr. @DoreenEzeife and team. I do believe early integration of liquid biopsy is appropriate as it increases the odds of making the right treatment choice quickly, particularly since sequence of therapy is so critical. These data are icing on the cake.

[Ivy Riano, M.D. @IvyLorena_Md]

📣Global Oncology Opportunity

We are excited to launch our Project ECHO Global Oncology Tumor Board 2021-22 @DartmouthHitch:

A unique platform that leverages learning, training and practice support to give voice to healthcare knowledge around the world

Registration is free

[Giannis Mountzios @g_mountzios]

My personal, by no means exhaustive highlights of #lungcancer @ other #thoraciccancer abstracts for upcoming #ESMO21. Pls feel free to add/share/RT/comment. Apologies if I miss any. Looking forward to the presentations!!
@OncoAlert @myESMO @ASCO @ASCOPost @IASLC @lcsmchat #some

[Tatiana Prowell, MD @tmprowell]

Wondering who is considered #immunocompromised in the eyes of #CDC #ACIP following yesterday’s #FDA authorization of a 3rd dose of Pfizer or Moderna #COVID19 #vaccine for this group?

[KizzyPhD @KizzyPhD]

1/n: And BOOM!!! Our immune correlates of protection manuscript is now fully peer reviewed!